This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: Dana-Farber-Cancer Institute Inc.. Active years: 2019-2024.
Company Filing History:
Years Active: 2019-2024
Title: Joseph Rosenbluh: Innovator in Cancer Treatment
Introduction
Joseph Rosenbluh is a notable inventor based in Brookline, MA (US). He has made significant contributions to the field of cancer treatment through his innovative research and patented methods. With a total of 2 patents, Rosenbluh is dedicated to advancing therapeutic strategies for cancer patients.
Latest Patents
Rosenbluh's latest patents focus on methods of treating cancer that involve the active Wnt/β-catenin pathway. The inventions provide methods for treating subjects with Wnt/beta-catenin active cancer by administering compounds that inhibit the expression or activity of specific proteins such as YES1, BIRC5, or BCL2L1. Additionally, these methods include compounds that inhibit YAP1-beta-catenin complex formation and binding to DNA. The compounds can take various forms, including nucleic acids, peptides, antibodies, or small molecules. Furthermore, the patents encompass methods for screening therapeutic targets for cancer treatment.
Career Highlights
Joseph Rosenbluh is affiliated with the Dana-Farber Cancer Institute Inc., where he conducts his research and develops his innovative treatments. His work is pivotal in the ongoing fight against cancer, and he continues to explore new avenues for therapeutic intervention.
Collaborations
Rosenbluh collaborates with esteemed colleagues in the field, including William C. Hahn, to enhance the impact of his research and broaden the scope of cancer treatment methodologies.
Conclusion
Joseph Rosenbluh's contributions to cancer treatment through his patented methods highlight his commitment to innovation in the medical field. His work not only advances scientific understanding but also offers hope for improved therapeutic options for cancer patients.